Indies Q4 profit jumps sharply

Net profit increased 46 percent to $199 million at Indies Pharma, for the year to October, over the 2019 period and jumped 78.5 percent for the October quarter to $40 million.
Revenues increased 5 percent for the year to $766 million and a much stronger 33 percent for the final quarter, to $200 million over the same period in 2019 with $150 million.
There “would have seen a significant growth in its revenues if it were not for the pandemic,” Vishnu V. Muppuri, Executive Director & COO, stated in the report to shareholders. Revenues for the company’s first quarter to January increased 15 percent and 7.3 percent for the second quarter. The June quarter was out of line with a fall of 23 percent. Growth in revenues since 2017 has reached 15 cents in just 2018.
Gross profit for the twelve-month period was $525 million representing a 14 percent increase over the similar period in 2019. The company enjoys a high gross profit margin, which is a great asset. The margin rose to 69 percent for the year from 63 percent in 2019 and from 62 percent in 2018.
Administrative and other expenses decreased by $18.4 million to $320 million for the year from 2019, mainly due to the decline in rent, vehicle expenses, IT, security and one-off expenses incurred in the prior year. In the final quarter, Administrative and other expenses also dropped from $96 million to $74 million. Finance cost rose from just $197,000 in 2019 to $13.8 million in 2020, with the increased borrowing, taken on the finance the building of a corporate office, increased warehousing capacities and fund the development and approval of two new drugs in the United States.

Vishnu Muppuri – Executive director of Indies.

Earnings per share for the twelve-month period rose to 15 cents per share compared to 10 cents in the prior 2019 period.
Shareholders’ equity increased from $695 million at the end of the previous year to $779 million resulting from a revaluation gain of $71 million on the company’s property and an increase in retained earnings. Long-term Liabilities increased to $882 million from just $8 in 2019.
The Company generated positive cash inflows of $247 million; working capital and related party advances reduced the amount to $191 million. Loans net of repayment, purchase of property and $187 million dividend payment left the cash and equivalent at $44 million.
Current assets rose from $624 million in 2019 to $975 million at the end of 2020, with a rise in cash funds accounting for $330 million of the increase. Inventories slipped to $147 million from $157 and receivables moved up slightly from $293 million to $314 million, representing more than four months of sales. Current liabilities stood at just $44 million. The company reports rising amounts due to related company and director and sends a highly negative message about the financing of the business and those closely connected to it.
The company’s stock that is listed on the Junior Market of the Jamaica Stock Exchange seems fully valued at $2.70, with a PE of 18 times 2020 earnings and 13.5 times’s forecast of 20 cents per share for 2021.

About IC